glp-1 and kidney function receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal Glucagon-like peptide 1(GLP-1) receptor agonists
Description
Exploring the emerging research on GLP-1 receptor agonists and Parkinson's disease: understand the science, clinical trials, potential benefits, risks, and why these diabetes medications are being investigated for neuroprotection.
For adults, take 2mL (approx 4 pumps) 2 times per day, preferably 15 to 30 minutes before meals, or as directed by a healthcare professional
There can be side effects and risks: GLP-1 drugs affect multiple systems (pancreas, kidney, GI tract) and are not without cost or health implications
A licensed physician will determine if treatment is appropriate for you
Designed to complement a structured nutrition and lifestyle approach
